CLAIMS

1. Use of a fusion protein comprising a hepatitis B PreS polypeptide fused to a peptide consisting of amino acid sequence SEQ ID NO: 1, a peptide consisting of amino acid sequence SEQ ID NO: 2, a peptide consisting of amino acid sequence SEQ ID NO: 3 and a peptide consisting of amino acid sequence SEQ ID NO: 4 in the manufacture of a medicament for the treatment or prevention of a hepatitis B virus infection.

2. Use according to Claim 1, in which the amino acid sequence of the PreS polypeptide consists of SEQ ID NO: 5.

3. Use according to Claim 1 or 2, in which the peptides consisting of amino acid sequences SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4 are fused to the N- and/or C-terminus of the PreS polypeptide.

4. Use according to Claim 1, 2 or 3, in which the fusion protein consists of amino acid sequence SEQ ID NO: 6.

5. Use according to any preceding claim, in which the hepatitis B virus infection is caused by a hepatitis B virus genotype A, B, C, D, E, F, G, H or a subtype thereof.

6. Use according to any preceding claim, in which the fusion protein is to be administered to an individual at least once in an amount of 0.01 µg/kg body weight to 5 mg/kg body weight, preferably 0.1 µg/kg body weight to 2 mg/kg body weight.

7. Use according to any preceding claim, in which the fusion protein is to be administered together with at least one adjuvant and/or pharmaceutical acceptable excipient.